ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
3B BlackBio Dx reported Q1FY27 consolidated revenue of ₹33.49 Cr, up 50% YoY, driven by the Coris BioConcept acquisition. Core MDx business grew 17.4% excluding Coris.
3B BlackBio reported FY26 consolidated revenue of ₹142 cr and PAT of ₹60 cr, driven by diagnostic growth and contributions from Coris BioConcept and TRUPCR Europe.
3B BlackBio reported strong FY26 consolidated revenue of ₹142cr with a PAT of ₹60cr, driven by European acquisitions despite slower domestic molecular diagnostic growth.
3B BlackBio Dx delivered strong consolidated growth in FY26, driven by the acquisition of Coris BioConcept. Strategy focuses on expanding the Molecular Diagnostics (MDx) portfolio and international market penetration.